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Abstract
Bacterial peptidoglycan-derived muramyl dipeptide (MDP) and derivatives have long-recognized antiviral properties but
their mechanism of action remains unclear. In recent years, the pattern-recognition receptor NOD2 has been shown to
mediate innate responses to MDP. Here, we show that MDP treatment of mice infected with Influenza A virus (IAV)
significantly reduces mortality, viral load and pulmonary inflammation in a NOD2-dependent manner. Importantly, the
induction of type I interferon (IFN) and CCL2 chemokine was markedly increased in the lungs following MDP treatment and
correlated with a NOD2-dependent enhancement in circulating monocytes. Mechanistically, the protective effect of MDP
could be explained by the NOD2-dependent transient increase in recruitment of Ly6C
high ‘‘inflammatory’’ monocytes and, to
a lesser extent, neutrophils to the lungs. Indeed, impairment in both Ly6C
high monocyte recruitment and survival observed
in infected Nod2-/- mice treated with MDP was recapitulated in mice deficient for the chemokine receptor CCR2 required for
CCL2-mediated Ly6C
high monocyte migration from the bone marrow into the lungs. MDP-induced pulmonary monocyte
recruitment occurred normally in IAV-infected and MDP-treated Ips-1-/- mice. However, IPS-1 was required for improved
survival upon MDP treatment. Finally, mycobacterial N-glycolyl MDP was more potent than N-acetyl MDP expressed by most
bacteria at reducing viral burden while both forms of MDP restored pulmonary function following IAV challenge. Overall,
our work sheds light on the antiviral mechanism of a clinically relevant bacterial-derived compound and identifies the NOD2
pathway as a potential therapeutic target against IAV.
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Introduction
Extending from the concept of vaccination employed by
Edward Jenner more than two centuries ago, early studies
performed with Freund’s complete adjuvant have contributed to
establish the notion that microbial organisms could be decom-
posed and still retain immunostimulatory properties. Freund’s
original preparation consisting of heat-killed mycobacterial cells
suspended in mineral oil, could indeed be recapitulated by the cell
wall fraction of mycobacteria and related organisms [1]. The
smallest bacterial cell wall constituent that retained immunogenic
properties was identified as the peptidogylcan N-acetylmuramyl-L-
alanyl-D-isoglutamine substructure, commonly referred to as
MDP [2]. This molecule was synthesized and found to have
antibacterial, antiviral and tumoricidal activity [3–5]. Since then,
an impressive number of MDP derivatives were generated, some
of which have reached clinical trials for the treatment of infectious
diseases and cancer or as vaccine adjuvant [6–8]. However, the
mechanism of action of MDP still remains unknown.
In 2003, the NOD-like receptor NOD2 was identified as the
host PRR responsible for MDP recognition [9]. Upon MDP
sensing, NOD2 activates mitogen-activated protein (MAP) kinases
as well as the transcription factors NF-kB and IRF5 via the RIP2
adaptor molecule leading to the secretion of inflammatory
mediators, chemokines and type I IFNs [10–12]. Since the
discovery of NOD2, it has been assumed, but never formerly
demonstrated, that the antiviral activity of MDP requires this
receptor. However, a growing body of evidence suggests that
NOD2 triggering could effectively be beneficial against several
viral infections including IAV. First, stimulation of macrophages
with MDP is known to induce the production of type I IFNs [12],
which are required to control IAV infection [13,14]. In addition,
NOD2 has been shown to play a role in the recognition of viral
single-stranded RNA (ssRNA) and to activate antiviral innate
immunity via the IPS-1 adaptor molecule [15]. A recent study also
shows that NOD2 promotes the CCL2-CCR2-dependent re-
cruitment of Ly6C
high monocytes in the intestine of Citrobacter
rodentium-infected mice [16]. In parallel, Seo and colleagues have
demonstrated an indispensable and protective role for type I IFN
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high
monocytes during IAV infection [17]. Therefore, the dual role
of NOD2 in monocyte recruitment and type I IFN production
deserves closer attention in relationship with the protective action
of MDP against viral infection.
In this report, we define a mechanism for the antiviral activity of
MDP against IAV, which requires NOD2-dependent induction of
lung CCL2 and type I IFN as well as NOD2- and CCR2-
dependent recruitment of Ly6C
high monocytes to the lungs. We
also demonstrate that the protective effect of MDP treatment
necessitates the IPS-1 adaptor molecules involved in IAV
recognition to be functional. Furthermore, we show that N-
glycolyl MDP, a naturally occurring derivative of the classical N-
aceyl MDP, is more potent at reducing viral burden and that
treatment with both forms of MDP restores pulmonary function
following IAV infection.
Results
MDP treatment depends on NOD2 to improve survival of
IAV-infected mice and to reduce pulmonary viral load
and inflammation
MDP and synthetic derivatives have been reported to exhibit
antiviral activity against IAV [18–20]. In our infection model,
daily administration of 10 mg/kg MDP intravenously (iv.) starting
at day 1 and ending at day 6 post-infection (pi.) with a sub-lethal
dose of IAV was sufficient to significantly reduce viral titers in the
lungs of mice (Figure S1). To verify if the protective effect of MDP
treatment against IAV depends on NOD2, we first infected wild-
type (WT) and Nod2-/- mice with a lethal dose of IAV equivalent
to ten times the LD50 and treated them with saline or MDP. As
shown in Figure 1A, WT animals treated with MDP featured
significantly increased survival (left panel) and decreased weight loss
(right panel) when compared to their saline-treated counterpart.
Conversely, MDP treatment of Nod2-/- animals did not affect
survival and body weight loss as compared to saline-treated
Nod2-/- animals. No significant difference in survival and body
weight loss was observed between saline-treated WT and Nod2-/-
mice with high dose IAV challenge.
In order to better dissect the NOD2-dependent antiviral activity
of MDP during the course of IAV infection, WT and Nod2-/- mice
were infected with a sub-lethal dose of virus and treated or not
with MDP as described above. In WT animals, MDP treatment
caused a one-log decrease in lung viral loads at day 3 and 5 pi. as
compared to saline-treated controls (Figure 1B). No decrease was
observed in MDP-treated Nod2-/- mice and no significant
difference in viral load could be observed between WT and
Nod2-/- mice treated with saline. Upon histological examination of
the lungs, we noticed a marked reduction in leukocyte infiltration
as well as decreased airway plugging and alveolar wall thickening
in MDP-treated WT mice at day 5 and 7 pi. as compared to
saline-treated control animals (Figure 1C). However, the ability of
MDP treatment to restore the pulmonary architecture was absent
in Nod2-/- mice at both day 5 and 7 pi. Collectively, these results
show that the protective antiviral activity of MDP against IAV is
dependent on NOD2.
MDP treatment causes NOD2-dependent modulation of
lung cytokine production during the course of IAV
infection
Considering dysregulated immune inflammatory response is the
major cause of pathology associated with IAV infection, we next
characterized the inflammatory state of the lungs upon MDP
treatment during the course of IAV infection. We first measured
a panel of inflammatory cytokines directly from lung homogenates
of infected WT and Nod2-deficient mice treated or not with MDP.
In MDP-treated WT mice, levels of IL-6 and TNF-a were
significantly reduced at day 5 pi. (Figure 2A–B). The rise in both
IL-6 and TNF-a production between day 5 and day 7 in WT mice
treated with MDP to a similar level than saline-treated animals
suggests that these cytokines are required for the control and/or
resolution of IAV infection but that a delay in their production
could be beneficial to the host. Indeed, it has recently been shown
that both IL-6 and TNF-a were essential in the late phase of IAV
infection by promoting neutrophil survival and viral clearance [21]
as well as by down-modulating the extent of lung immunopathol-
ogy [22] respectively. Interestingly, Nod2-/- mice showed an early
and significant increase in lung IL-6 but not TNF-a as compared
to saline-treated WT animals at day 3 pi. irrespective of treatment,
a finding that was recapitulated during in vitro alveolar macro-
phage infection (Figure 2A–B and Figure S2A–B). Despite its low
level of secretion, IL-10 tended to be reduced at days 5 and 7 pi. in
WT mice treated with MDP relative to untreated WT mice
consistent with the documented positive correlation between this
cytokine and viral load [23] (Figure 2C). No significant difference
in the production of IL-12p70 (Figure 2D) was detected in lungs of
MDP-treated WT mice as compared to saline-treated animals
during the course of the infection. Interestingly, CCL2 levels were
significantly increased at day 3 pi. in the lungs of WT animals
treated with MDP as compared to saline-treated controls
(Figure 2E). Such increase observed at day 3 in MDP-treated
relative to saline-treated mice was transient since CCL2 pro-
duction was significantly lower in mice administered with MDP at
day 5 pi. before rising again at day 7. Importantly, the modulatory
effect of MDP treatment on lung cytokine production during IAV
infection was dependent on NOD2 since no significant difference
in levels of all measured cytokines could be observed between
MDP-treated and saline-treated Nod2-deficient mice (Figure 2A–
E).
Type I IFNs are critical for the control of IAV infection [13,14]
and IAV is known to suppress their production during the early
phase of infection [24]. On the other hand, MDP is known to
cause NOD2-dependent induction of type I IFNs via RIP2 and
IRF5 [12]. We therefore measured the levels of type I IFNs in lung
homogenates of IAV-infected WT and Nod2-deficient mice treated
or not with MDP. Consistent with published findings [15], IFN-
b tended to be reduced in the lungs of infected Nod2-/- mice as
compared to WT animals during the early phase of infection and
Nod2-/- alveolar macrophages produced significantly less IFN-
b than WT cells in response to IAV (Figure 2F and Figure S2C). In
sharp contrast to inflammatory cytokines (IL-6, TNF-a), MDP
treatment of WT mice significantly increased both IFN-b and
IFN-a production in the lungs as compared to saline-treated mice
at day 3 pi. (Figure 2F–G). Again, the effect of MDP treatment
was NOD2-dependent since there was no difference in induction
of type I IFN in MDP-treated Nod2-deficient animals during the
course of infection. In recall experiments, total lung cells derived
from infected WT mice treated with MDP and re-challenged ex
vivo with virulent IAV also produced increased type I IFN and
inhibited IAV replication in a NOD2-dependent manner (Figure
S3). Altogether, these findings show that during the course of IAV
infection, MDP treatment modulates the production of inflam-
matory cytokines in a NOD2-dependent fashion and causes an
early and NOD2-dependent increase in CCL2 and type I IFNs.
NOD2-Dependent Antiviral Activity of MDP
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the pool of circulating monocytes
Monocytes are a multipotent subset of bone marrow-derived
cells that can migrate to infected tissues and further differentiate
into specialized types of macrophages and dendritic cells [25].
MDP has previously been shown to stimulate hematopoiesis when
administered systemically [6]. In addition, the secretion of CCL2
and type I IFNs, which have well-characterized functions in
monocyte recruitment [25], was enhanced in the lungs of IAV-
infected and MDP-treated mice in a NOD2-dependent fashion
(Figure 2E–G). Therefore, we investigated the effect of treatment
on the number of circulating monocytes as well as neutrophils.
Blood was collected from WT and Nod2-deficient mice infected or
not with IAV and treated or not with MDP and cells were stained
with Abs against CD11b, CD115 and Gr1 to identify monocytes
(CD11b
+CD115
+) and neutrophils (CD11b
+CD115
2Gr1
+).
Figure 3A shows representative dot plots obtained at day 5 pi.
and results are quantified in Figures 3B and 3C. In infected and
uninfected WT animals treated with MDP, the number of
circulating monocytes was significantly enhanced at day 5 pi. as
compared to infected animals treated with saline (Figure 3B, left
panel). In contrast, although MDP treatment tended to decrease
the number of blood neutrophils at day 5 pi., no significant
difference could be observed between infected and uninfected
mice treated with MDP or between infected mice treated or not
with MDP (Figure 3B, right panel). The effect of MDP was NOD2-
dependent since no significant difference was observed between all
groups in the number of blood monocytes and neutrophils in Nod2-
deficient mice (Figure 3C). Therefore, systemic administration of
MDP causes a selective increase in circulating monocytes that is
dependent on NOD2 and independent on IAV infection.
Figure 1. MDP treatment depends on NOD2. Top (in bold): Schematic representation of daily treatment with MDP following IAV infection. (A)
WT and Nod2-/- mice (n=10/group) were infected in. with IAV (3000 PFU) and treated daily for 6 days with either saline or MDP (intravenous
administration, iv.). Survival (left panel) and body weight (right panel) was monitored daily. Data shown are representative of three independent
experiments (*p#0.05 as compared to saline-treated mice, log-rank test). (B–C) WT and Nod2-/- mice (n=5/group) were infected in. with IAV (50 PFU)
and treated as in A. Mice were sacrificed at day 3, 5 and 7 pi. and viral loads were determined from homogenized lungs (B). At day 5 and 7, upper left
lobes were harvested and stained with H&E for histological examination by microscopy at 1006magnification (C). A: example of alveolar structure; B:
example of bronchiolar structure. Data shown are representative of three independent experiments (*p#0.05 as compared to saline-treated mice, t-
test).
doi:10.1371/journal.pone.0036734.g001
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increase in recruitment of Ly6C
high monocytes to the
lungs of IAV-infected mice
A recent report by Seo and colleagues suggests that the
protective effect of type I IFNs during IAV infection is linked to
their role in triggering the preferential recruitment of Ly6C
high
monocytes via MCP-1 (also known as CCL2) over neutrophils to
the lungs [17]. Since we observed a NOD2-dependent increase in
CCL2, type I IFNs and circulating monocytes following MDP
treatment of IAV-infected mice (Figure 2E–G and Figure 3), we
investigated whether such treatment affected populations of
monocytes, neutrophils and macrophages in the lungs during the
course of infection. To do so, total lung cells and bronchoalveolar
lavage (BAL) cells from WT and Nod2-/- mice infected or not with
IAV and treated or not with MDP were isolated and stained with
Abs against F4/80, CD11c, CD11b, Gr1 and Ly6C. Cells were
then gated by flow cytometry to identify macrophages (F4/
80
highCD11c
high), monocytes (CD11b
+Gr1
int) and neutrophils
(CD11b
+Gr1
high). To identify inflammatory monocyte subsets,
monocyte population was gated back with CD11b
+Ly6C
high and
this cell population was further analyzed for TNF-a secretion in
infected and treated WT and Nod2-/- mice. Figure 4A and Figure
S4 serve as a representative examples and quantification is
depicted in Figures 4B–C (lungs) and 4D–E (BAL). In WT mice
infected or not with IAV and treated with MDP, the relative
number of monocytes in the lungs was significantly enhanced at
day 3 and 5 pi. when compared to IAV-infected mice treated with
Figure 2. MDP treatment causes NOD2-dependent modulation of pulmonary cytokines. (A–G) WT and Nod2-/- mice (n=5/group) were
infected in. with IAV (50 pfu) and treated daily with either saline or MDP (iv.). Prior to infection and at day 3, 5 and 7 pi., levels of various cytokines
were determined from homogenized lungs. Data shown are representative of two independent experiments (*p#0.05 as compared to saline-treated
WT mice, t-test).
doi:10.1371/journal.pone.0036734.g002
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uninfected mice also induced a transient and significant increase in
the relative number of Ly6C
hi monocytes as compared to saline-
treated IAV-infected mice at day 3 pi. (Figure 4B, top right panel).
This increase in proportion of Ly6C
high monocytes in MDP-
treated mice was accompanied by a transient increase in the
proportion of neutrophils (Figure 4B, bottom left panel) while the
macrophage fraction did not vary significantly between MDP-
treated groups and between IAV-infected groups (Figure 4B, bottom
right panel). In Nod2-deficient animals, MDP treatment did not
cause any difference in the relative number of lung monocytes,
Ly6C
high monocytes, neutrophils and macrophages during the
Figure 3. MDP treatment enhances the number of blood monocytes. (A–C) WT and Nod2-/- mice (n=3/group) were infected or not in. with
IAV (50 pfu) and treated daily with either saline or MDP (iv.). At day 5 pi., blood cells were subjected to flow cytometry (A). Mono: monocytes; Neutro:
neutrophils. Numbers indicate cell population percentages within gates. Relative number of monocytes and neutrophils were determined in naı ¨ve
mice and at day 3 and 5 pi. (B and C). Data shown are representative of two independent experiments (*p#0.05 as compared to IAV-infected and
saline-treated mice, t-test).
doi:10.1371/journal.pone.0036734.g003
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e36734Figure 4. MDP treatment causes NOD2-dependent recruitment of Ly6C
high monocytes to the lungs. (A–E) WT and Nod2-/- mice (n=3/
group) were infected or not in. with IAV (50 pfu) and treated daily with either saline or MDP (iv.). At day 3 pi., total lung cells were subjected to flow
cytometry (A). Mac: macrophages; Mono: monocytes; N: neutrophils. Numbers indicate cell population percentages within gates. Relative number of
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phenotype, Ly6C
high monocytes from both WT and Nod2-/- mice
infected with IAV and treated with MDP secreted TNF-
a (Figure 4A, bottom).
In the BAL, monocytes were increased at day 3 pi. in IAV-
infected WT animals treated with MDP as compared to those
treated with saline (Figure 4D, top left panel and Figure S4). Similar
to what was observed in the lungs, relative numbers of Ly6C
high
monocytes (Figure 4D, top right panel) and neutrophils (Figure 4D,
bottom left panel) were transiently increased in the BAL of IAV-
infected and MDP-treated WT mice at day 3 pi. although
neutrophils did not reach statistical significance. Alveolar macro-
phages remained unaffected by MDP treatment in the BAL of
IAV-infected mice (Figure 4D, bottom right panel). Interestingly,
while MDP treatment had similar effect in infected and uninfected
WT mice with respect to the modulation of cellular populations in
the blood and lung tissue, MDP alone did not cause any change in
the relative number of all cell types investigated in the BAL
(Figure 4D). In Nod2-deficient mice, MDP treatment did not have
any significant effect on the relative number of monocytes,
Ly6C
high monocytes, neutrophils and macrophages either when
comparing IAV-infected groups treated or not with MDP or when
comparing mice treated with MDP alone at day 3 and 5 to
baseline (day 0) (Figure 4E). Therefore, MDP treatment causes
a transient NOD2-dependent increase in pulmonary Ly6C
high
monocytes and, to a lesser extent, neutrophils. This increase
occurs in lung tissue in the presence or absence of IAV infection
but occurs in the airways only in IAV-infected mice.
The protective activity of MDP treatment against IAV
depends on CCR2 and IPS-1
Migration of Ly6C
high monocytes from the bone marrow occurs
when CCL2 binds to its receptor CCR2 expressed at high levels
on these cells [26]. To ask whether CCR2 is required for the
protective effect of MDP-treatment in IAV-infected mice, Ccr2-/-
animals were infected with a sub-lethal or a lethal dose of virus and
treated or not with MDP. As depicted in Figure 5A, Ccr2-deficient
mice infected with a sub-lethal dose of virus and treated with saline
failed to increase their frequency of Ly6C
high monocytes into the
lungs. In addition, MDP-treatment of these mice was unable to
cause an increase in the percentage of Ly6C
high monocytes as
compared to saline-treated controls at day 3 pi., unlike what was
observed in WT animals. Importantly, the protective effect of
MDP treatment upon infection with a lethal dose of virus was
CCR2-dependent since no difference in survival (Figure 5B, left
panel) and in body weight loss (Figure 5B, right panel) was observed
between saline- and MDP-treated Ccr2-deficient mice. Thus, the
protective effect of MDP treatment against IAV is linked to the
NOD2- and CCR2-dependent recruitment of Ly6C
high monocytes
to the lungs.
NOD2-mediated sensing of MDP is known to occur via RIP2,
independently of the IPS-1 adaptor molecule. However, IPS-1 acts
downstream of the RIG-I PRR implicated in IAV viral RNA
recognition [27]. To investigate whether MDP treatment could
have a protective effect on IAV-infected mice with compromised
innate response to the virus, Ips-1-/- animals were infected with
IAV and treated or not with MDP. Due to the importance of
Ly6C
high monocytes recruitment for the protective effect of MDP
treatment, we first verified if these cells were recruited following
treatment of knockout mice. Ips-1-deficient animals infected with
a sub-lethal dose of virus and treated with MDP all showed an
increased proportion of Ly6C
high monocytes in the lungs as
compared to uninfected mice and a further increase upon MDP
treatment as compared to saline-treated animals at day 3 pi.,
similar to WT mice (Figure 5A). Upon lethal challenge with IAV,
Ips-1-/- mice treated with MDP did not show any significant
difference in survival (Figure 5C, left panel) and weight loss
(Figure 5C, right panel) as compared to those treated with saline.
Thus, despite MDP treatment and Ly6C
high monocyte recruit-
ment, the immunomodulating activity of MDP during IAV
infection requires functional innate host response via IPS-1.
N-glycolyl MDP is more potent than N-acetyl MDP and
restores lung function in IAV-infected mice
The conversion of the N-acetyl group at carbon 2 of the
muramic acid moiety of MDP to a N-glycolyl group by
mycobacteria and related organisms has recently been demon-
strated to render the molecule more potent at activating NOD2-
and RIP2-dependent responses [12,28]. To ask whether this
modification would also improve the potency of MDP as
a treatment against IAV, WT mice were infected and treated
with various concentrations of both forms of MDP. As shown in
Figure 6A, 10 mg/kg N-acetyl MDP, the form and dose of MDP
used throughout this study, caused a significant reduction in IAV
viral load in the lungs as compared to saline-treated mice
(horizontal line, 1183961234 PFU/ml 610
3). At the same
10 mg/kg concentration, N-glycolyl MDP caused a similar de-
crease in viral load than N-acetyl MDP. However, upon de-
creasing the administered concentration, N-acetyl MDP could no
longer significantly reduce lung viral load while N-glycolyl MDP
remained active down to a concentration of 1.25 mg/kg. To
characterize the physiological impact of treatment with both forms
of MDP during IAV infection, we analyzed lung function in IAV-
infected mice treated or not with active concentrations of N-acetyl
MDP (10 mg/kg) or N-glycolyl MDP (1.25 mg/kg). At day 5 pi.,
animals were tracheotomized and ventilated using the flexiVent
apparatus in order to evaluate airway responsiveness to methacho-
line challenge and baseline elastance. Airway resistance and
pulmonary compliance to methacholine were respectively signif-
icantly enhanced and decreased in saline-treated IAV-infected
mice as compared to uninfected animals (Figure 6B and 6C). In
contrast, both parameters did not vary significantly from un-
infected mice in IAV-infected mice treated with active concentra-
tions of either form of MDP. In line with these results, pulmonary
elastance (reciprocal of compliance) measured prior to methacho-
line challenge was significantly enhanced in saline-treated IAV-
infected mice as compared uninfected mice while no difference
was observed in MDP-treated mice (Figure 6D). Taken together,
these results show that the N-glycolyl MDP derivative is more
potent than the classical MDP and that the antiviral activity of
MDP against IAV correlates with improved lung function.
Discussion
Following the discovery of NOD2 as a major susceptibility gene
for Crohn’s disease and as the host sensor for bacterial-derived
MDP, its role in promoting antiviral immunity has not surprisingly
beenneglecteddespitethelong-standingobservationthatMDPand
derivativescouldprovideprotectionagainstviralinfection.Thefirst
directlinkbetweenNOD2andantiviralimmunityhasrecentlybeen
monocytes, Ly6C
high monocytes, neutrophils and macrophages were determined in the lungs (B–C) and BAL (D–E) in mice and at day 3 and 5 pi. Data
shown are representative of three independent experiments (*p#0.05 as compared to IAV-infected and saline-treated mice, t-test).
doi:10.1371/journal.pone.0036734.g004
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NOD2indetectionofviralssRNA[15].Althoughmostinvivostudies
performedbythisgroupweredoneusingrespiratorysyncytialvirus,
the authors conclude that NOD2 acts as a general activator of
antiviral immunity against ssRNA viruses. While we did observed
NOD2-dependent IFN-b secretion by macrophages in response to
IAV,assRNAvirus(FigureS2),wecouldnotfindanymajorrolefor
NOD2 itself (independently of MDP treatment) in protection
againstIAVusingasub-lethaloralethaldoseofvirus(Figure1A–B).
Instead, we found that NOD2 was the host PRR responsible for the
antiviral activity of MDP and provided further explanations on the
mechanism underlying this effect.
MDP treatment modulated cytokine secretion in the lungs of
IAV-infectedmice.Theeffectoftreatmentwastransient,causingan
earlydecreaseinIL-6andTNF-aaswellasanincreaseintypeIIFN.
The net result of this altered cytokine balance might have been
reduced inflammation associated with excessive early IL-6 and
TNF-a secretion and increased viral clearance by overcoming the
NS1-mediatedinhibitoryeffectofthevirusontypeIIFNproduction
[24]. Later increase in IL-6 and TNF-a secretion in MDP-treated
miceuptoasimilarlevelthansaline-treatedanimalsmightalsohave
contributedtoprotectionsinceIL-6isknowntopromoteneutrophil
survival and function in the late phase of infection while TNF-
a deficiency has recently been demonstrated to exacerbate
immunopathology in a mouse model of acute IAV infection
[21,22]. While MDP has been shown to induce type I IFN via
IRF5 [12], the mechanism by which MDP treatment augmented
type I IFN secretion in the lungs remains unclear. The contribution
ofIRF5aswellasIRF3andIRF7activationbyIAVduringinfection
and MDP treatment is the subject of ongoing investigation.
A recent human study has shown that IAV is capable of infecting
monocytes irrespective of their cell surface phenotype and this cell
typewasmoreresistantthandifferentiatedmacrophagestothevirus
[29]. In our study, lung CCL2 levels and circulating blood
monocytes were increased in IAV-infected WT mice treated with
MDP. Within the pulmonary environment, we also observed
a NOD2-dependent relative increase in monocytes, more specifi-
callyintheLy6C
highmonocytesubset,inbothlungtissueandBALof
IAV-infected mice treated with MDP as opposed to those treated
with saline. Ly6C
high monocytes recruitment was dependent on
CCR2 and MDP treatment was ineffective in animals deficient in
this receptor. The role of Ly6C
high monocytes during IAV infection
is controversial. Ccr2-deficiency has been associated with decreased
immunopathology and mortality due to impaired macrophages
recruitment into the lungs of IAV-infected mice [30]. However, the
abilityofCcr2-/-micetoclearIAVwasalsoshowntobedelayeddue
to a blockage in recruitment of tipDCs to the lungs and decreased
primingofviralantigen-specificCD8Tcells[31].Inaddition,typeI
Figure 5. MDP treatment requires CCR2 and IPS-1. (A) WT, Nod-2-/-, Ccr2-/- and Ips-1-/- mice (n=3/group) were infected in. with IAV (50 pfu)
and treated daily with either saline or MDP (iv.). Frequency of Ly6C
high monocytes was determined in the BAL of naı ¨ve mice and in infected mice at
day 3 pi. Data shown are representative of two independent experiments (* p#0.05 as compared to naı ¨ve mice of the same genotype, **p#0.05 as
compared to saline-treated mice of the same genotype, t-test). (B and C) Survival (left panels) and body weight (right panels) was monitored daily in
WT, Ccr2-/- and Ips-1-/- mice (n=10/group) infected with a lethal dose of virus (3000 pfu) and treated as in A. Data shown are representative of two
independent experiments (*p#0.05 as compared to saline-treated mice, log-rank test).
doi:10.1371/journal.pone.0036734.g005
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positively regulate the influx of Ly6C
high monocytes into the lungs
[17].Therefore,whileexcessiverecruitmentofLy6C
highmonocytes
mightbedetrimentalduringpulmonaryIAVinfection,anearlyand
transient increase relative to other innate effector cells types such as
what we observed upon MDP treatment could be beneficial to
enhancebothviralclearanceandprimingofantigen-specificCD8T
cell response leading to a faster resolution of infection.
The control of adaptive immune responses by NOD2 is a subject
under intense investigation [32]. While systemic NOD2 stimula-
tion by MDP alone as been demonstrated to induce a T helper 2
(Th2) type of adaptive response, the generation of a Th1 response
following co-stimulation with MDP and Toll-like receptor (TLR)
agonists was NOD2-dependent [33]. Treatment with bacteria-
derived MDP during a viral infection such as IAV, which itself
activates an array of innate immune receptors including various
TLRs, may therefore be expected to enhance IAV-specific Th1
type immunity and potentially anti-IAV antibody titers. Indeed,
NOD2-dependent antibody production has recently been reported
in the context of streptococcal infection [34]. Efforts are currently
underway to evaluate the impact of MDP treatment and of
Ly6C
high monocytes recruitment on the unfolding of the adaptive
response in the lungs during IAV infection and in the context of
vaccination against the virus.
The ability of exogenous MDP to induce a NOD2-dependent,
transient increase in levels of various cytokines in the serum when
administered systemically has been well studied [33]. In addition,
we have shown here that MDP treatment alone in the absence of
IAV infection enhanced the number of circulating monocytes,
again via NOD2. Despite specific activation of the NOD2 PRR,
the protective action of immunomodulators such as MDP and
derivatives is not specific toward the pathogen per se and is often
described as a ‘‘boost of natural immunity’’. Clear evidence for
such an affirmation comes from the observation that mice deficient
in IPS-1, a key adaptor molecule in innate immunity to IAV [27],
cannot be protected by MDP treatment despite Ly6C
high
monocytes recruitment to the lungs. Hence, efforts are being
made in order to generate immunomodulatory compounds that
conserve protective ‘‘boosting’’ activity with minimal toxicity.
Examples include Murabutide, MDP-Lys (L18) (also known as
Romurtide) and L-MTP-PE (also known as Mifamurtide), three
MDP derivatives with low toxicity, which are promising for the
treatment of various infections and cancers such as HIV and
osteosarcoma [6,7,35–38]. In this study, we have shown that the
natural MDP derivative N-glycolyl MDP has a more potent
antiviral activity against IAV than the classical N-acetyl MDP,
consistent with the finding that N-glycolylation of MDP increases
its NOD2-stimulating activity [28]. Ongoing studies are aimed at
evaluating the toxicity of low dose N-glycolyl MDP and at
establishing whether it may have protective activity in different
models of viral infection and at different times following infection.
To conclude, the determination of key cellular and molecular
events induced by MDP treatment is expected to lead to a better
understanding of both the correlates of a protective response
against IAV and the mechanism of action of muramyl peptide
immunomodulators. In parallel, further investigation on the use of
clinically approved and novel MDP analogues for the immuno-
therapy of IAV infection should be considered.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory
Figure 6. N-glycolyl MDP is more potent than N-acetyl MDP. (A)
WT mice (n=5/group) were infected in. with IAV (50 pfu) and treated
daily with saline or various doses of N-acetyl MDP or N-glycolyl MDP
(iv.). Mice were sacrificed at day 3 pi. and viral loads were determined
from homogenized lungs. The line represents IAV viral load in the lungs
of saline-treated mice. (*p#0.05 as compared to saline-treated mice, t-
test). (B–D) WT mice (n=8/group) were infected or not in. with IAV
(50 pfu). From day 1 to day 4 pi., infected mice were treated daily with
either saline, N-acetyl MDP (10 mg/kg) or N-glycolyl MDP (1.25 mg/kg)
iv. At day 5 pi., airway resistance (B) and compliance (C) were both
measured upon methacholine challenge and baseline elastance (D) was
measured prior to methacholine administration using the flexiVent
apparatus. (* p#0.05 as compared to uninfected mice, t-test).
doi:10.1371/journal.pone.0036734.g006
NOD2-Dependent Antiviral Activity of MDP
PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e36734Animals of the Canadian Council on Animal Care (CCAC). The
protocol was approved by the Committee on the Ethics of Animal
Experiments of Universite ´ Laval (Permit Number: 09-121-2).
Mice
WT C57Bl/6 and Nod2-deficient mice were purchased from the
Jackson Laboratory(BarHarbor, Maine,USA). Ccr2-deficient mice
werekindlyprovidedbyDr.SergeRivest(CHUQResearchCenter,
Universite ´ Laval, Quebec, Canada). Ips-1-deficient mice were
kindly provided by Dr. Shizuo Akira (Osaka University, Osaka,
Japan). Nod2-/-, Ccr2-/- and Ips-1-/- breeding colonies were
established at the CHUQ Research Center. All study mice were 4
to 6 weeks old and experiments were conducted in accordance with
the guidelines of animal research ethics boards of Laval University.
Virus, cells and reagents
All infections were performed with Influenza virus strain A/
Puerto Rico/8/34 (H1N1). IAV was propagated and isolated from
Madin-Darby canine kidney (MDCK) cells and titrated using
standard plaque assay in MDCK cells [39]. The MDCK cell line,
alveolar macrophages and total lung cells (10
5 cells/well, 96-well
plate) were cultured in MEM supplemented with 10% heat-
inactivated FBS and gentamycin sulfate (40 mg/ml). N-acetyl
MDP and N-glycolyl MDP were purchased from Invivogen (San
Diego, CA, USA) and reconstituted with endotoxin-free water
(Invivogen).
Virus infection of mice and treatment
For in vivo protocols, as summarized in Figure 1 (top panel), mice
were infected in. at day 0 with 50 PFU of IAV except for survival
experiments where mice were infected with 3000 PFU of the virus.
Animals were randomized at day 1 and then treated iv. with saline
(NaCl 0.9%) or with reconstituted MDP dissolved in saline at the
appropriate concentration (1.25–15 mg/kg) daily from day 1 up to
day 6 pi. For survival experiments (3000 PFU IAV), animals were
monitored daily for health status and weight determination for up
to 14 days post-infection. For all other experiments (50 PFU IAV),
animals were sacrificed at day 3, 5 or 7 pi. and lungs were
harvested and homogenized for viral load determination by
standard plaque assay in MDCK cells.
Cyokine measurement
IL-6, TNF-a, IL-10, IL-12p70 and CCL2 concentrations were
determined directly from lung homogenates (expressed as pg/ml of
homogenized lungs, homogenized in 1 ml) or cell culture superna-
tant using the BD Cytometric Bead Array (CBA) mouse in-
flammatorykit(BDBiosciences,SanDiego,CA,USA)andanalyzed
using BD FACSArray Bioanalyzer System (BD Biosciences,
Ontario, Canada). Concentrations of IFN-a and IFN-b were
determined by ELISA (PBL InterferonSource, Piscataway, NJ,
USA).
Flow cytometry
Single-cell suspensions obtained from blood, collagenase- and
DNase-treated lungs or BALs were first incubated with anti-
CD16/32 (BioLegend, San Diego, CA, USA) to block non-specific
Ab interaction with Fc receptors. Then, cells were stained with
V500-conjugated anti-CD45 (BD Biosciences, San Diego, CA,
USA) as an appropriate gating strategy to visualize granulocytes
and mononuclear cell populations, with APC-conjugated anti-
CD115 (BioLegend, San Diego, CA, USA), V450-conjugated anti-
Gr1 (Ly6C/Ly6G) (BD Biosciences, San Diego, CA, USA), PE-
Cy7-conjugated anti-F4/80 (BioLegend, San Diego, CA, USA),
APC-Cy7-conjugated anti-CD11b and FITC-conjugated anti-
CD11c (BD Biosciences, San Diego, CA, USA). For intracellular
cytokine staining, cells were treated with GolgiPlug (BD
Biosciences, San Diego, CA, USA) for 5 h. Cells were washed
and blocked with anti CD16/32 followed by staining with
appropriate Abs against cell surface markers. Cells were then
washed, permeabilized, and stained according to the manufac-
turer’s instructions with FITC-conjugated anti-TNF-a (BD Bios-
ciences, San Diego, CA, USA). Flow cytometry was performed
using BD LSR II (BD Biosciences, Ontario, Canada) with
FACSDiva software Version 6.1.2 (BD Biosciences, Ontario,
Canada) on 100,000 cells per sample. Analysis was performed
using FlowJo Software (Tree Star Inc., Ashland, OR, USA).
Analysis of pulmonary function
Mice were anaesthetized with ketamine-xylazine (100 mg/kg
ketamine, 10 mg/kg xylazine), tracheotomized and connected to
a small animal ventilator (flexiVent, SCIREQ, Inc., Montreal,
Quebec, Canada). Then, animals were paralyzed with pancur-
onium (0.033 mg/kg) and canulated at the level of the jugular
vein. Mice were ventilated with a tidal volume of 10 ml/kg,
inspiratory/expiratory ratio of 66.67%, respiratory rate of 150/
min. Positive end-expiratory pressures (PEEP) were maintained by
submerging the expiratory limb from the ventilator into a water
trap (2.5–3 cm H2O pressure). Increasing concentrations of
methacholine (0.03–1 mg/kg) were injected iv. via the jugular
vein. Baseline resistance was restored before each subsequent
methacholine administration. The flexiVent apparatus ventilates
the mouse and then generates pressure–volume curves over 15 sec.
intervals where a snapshot measured is obtained before continuing
the respirations. The flexiVent is calibrated for gas compressibility
and resistive and accelerative losses in all the connections and
calculates resistance, compliance and elastance on the basis of the
entered mouse weight using the flexiVent 5.1 software.
Statistical analysis
Student’s t tests (two-tailed, unpaired) were performed except
for survival experiments where data were analyzed by the log-rank
test using the XLSTAT software (Addinsoft). Differences were
considered significant at p#0.05.
Online supplemental material
Figure S1 demonstrates the MDP dose-response of mice
infected with IAV. Figure S2 compares WT and Nod2-/- alveolar
macrophages treated with MDP or infected with IAV. Figure S3
shows results from ex vivo recall experiments performed with WT
and Nod2-/- mice. Figure S4 depicts the flow cytometry analysis of
cellular recruitment in the BAL of WT and Nod2-/- mice infected
or not with IAV and treated or not with MDP.
Supporting Information
Figure S1 WT mice (n=5/group) were infected in. with IAV
(50 PFU) and treated daily for 6 days with either saline or
indicated doses of MDP (iv.). Mice were sacrificed at day 3, 5 and
7 pi. and viral loads were determined from homogenized lungs.
Data shown are representative of two independent experiments.
(TIF)
Figure S2 Alveolar macrophages from naı ¨ve WT and Nod2-/-
mice were left untreated or were stimulated with MDP (10 mg/ml)
or IAV (1 MOI) for 24 h (A–C). IL-6, TNF-a and IFN-b levels
were determined from cell culture supernatants. Data shown are
NOD2-Dependent Antiviral Activity of MDP
PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e36734representative of two independent experiments (*p#0.05 as
compared to WT cells under the same condition, t-test).
(TIF)
Figure S3 (A–B) WT and Nod2-/- mice (n=3/group) were
infected and treated daily with either saline or MDP (iv.). At day
3 pi., total lung cells from infected and treated WT and Nod2-/-
mice were cultured ex vivo. Adherent cells were re-infected with
IAV (1 MOI) for 16 hours. IFN-b and IFN-a (A) levels as well as
viral loads (B) were determined from cell culture supernatants.
Data shown are representative of two independent experiments
(*p#0.05 as compared to saline-treated mice, t-test).
(TIF)
Figure S4 WT and Nod2-/- mice (n=3/group) were infected or
not with IAV and treated daily with either saline or MDP (iv.). At
day 3 pi., BAL cells were subjected to flow cytometry analysis.
Mac: macrophages; Mono: monocytes; N: neutrophils. Numbers
indicate cell population percentages within gates. Data shown are
representative of three independent experiments.
(TIF)
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